View DividendRegnum 경영진경영진 기준 점검 0/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보 최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간데이터 없음최근 경영진 업데이트공시 • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.모든 업데이트 보기Recent updates공시 • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.공시 • Aug 17Regnum Corp. announced delayed 10-Q filingOn 08/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17Regnum Corp. announced delayed 10-Q filingOn 05/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01Regnum Corp. announced delayed annual 10-K filingOn 03/31/2022, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Sep 02SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction.SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.공시 • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2021, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 03Regnum Corp. announced delayed annual 10-K filingOn 04/01/2021, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2020, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.CEORegnum에는 CEO가 없거나 해당 데이터가 없습니다.View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/10/09 20:47종가2024/07/12 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Regnum Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.
공시 • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.
공시 • Aug 17Regnum Corp. announced delayed 10-Q filingOn 08/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17Regnum Corp. announced delayed 10-Q filingOn 05/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01Regnum Corp. announced delayed annual 10-K filingOn 03/31/2022, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Sep 02SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction.SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.
공시 • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2021, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 03Regnum Corp. announced delayed annual 10-K filingOn 04/01/2021, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2020, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.